A Phase II Study to Evaluate the Efficacy and Safety of HLX43 in Patients With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer
Clinical trial NCT07459738 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07459738
- Sponsor
- Shanghai Henlius Biotech
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-04-01
- Primary completion
- 2026-12-30
- Enrollment
- 60
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.